Condition: Early-stage Breast Cancer · Estrogen-receptor-positive Breast Cancer · Sponsor: Jules Bordet Institute
Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer. To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug. Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs
This description comes directly from the study's public registry record.
Imane Bachir, MD · +3225413601 · imane.bachir@bordet.be
Marion Maetens, PhD · +3216321194 · marion.maetens@kuleuven.be
Always discuss trial participation with your own doctor first.
| Institut Jules Bordet | Brussels, Brussels Capital, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06150898